J Mater Chem 2008, 18:615–620.CrossRef 2. Zhi Ping X, GQ Max L: Layered double hydroxide nanomaterials as potential cellular drug delivery agents. Pure Appl Chem 2006,78(9):1771–1779. 3. Poewe W, Antonini W, Zijlmans JC, Burkhard PR, Vingerhoets F: Levodopa in the treatment of Parkinson’s disease:
an old drug still going strong. Clin Interv Aging 2010, 5:229–238. 4. Aminu Umar K, Samer Hasan Hussein Al A, Mohd Zobir H, Sharida F, Palanisamy A: Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. Int J Nanomedicine 2013, 8:1103–1110. 5. Aminu Umar K, Samer Hasan H-A-A, Mohd Zobir H, Sharida F: Preparation of Tween 80-Zn/Al-levodopa-layered double hydroxides nanocomposite for drug delivery system. Sci World J 2014, 10. Article Citarinostat concentration ID 104246 6. Suna W, Xiea C, Huafang Wang YH: Specific role of polysorbate 80 Caspase inhibitor coating on the targeting of nanoparticles to the brain. Biomaterials 2004, 25:3065–3071.CrossRef 7. Debanjan D, Senshang L: Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J Pharm Sci 2005,94(6):1343–1353.CrossRef
8. OECD: OECD guidelines for testing of chemicals. No 407: repeated dose 28-day oral toxicity study in rodents. Paris: Organisation for Economic Co-operation and Development; 2008.CrossRef 9. Redfern WS, Ewart LC, Pierre L, Mark P, Sally R, Jean-Pierre V: Functional assessments in repeat-dose toxicity studies: the art of the possible. Toxicol Res 2013, 2:209–234.CrossRef 10. Prasad LY2090314 in vivo Dolichyl-phosphate-mannose-protein mannosyltransferase AS: Zinc in human health: effect of zinc on immune cells. Mol Med 2008,14(5–6):353–357. 11. Dandekar P, Dhumal R, Jain R, Tiwari D, Vanage G, Patravale
V: Toxicological evaluation of pH-sensitive nanoparticles of curcumin: acute, sub-acute and genotoxicity studies. Food Chem Toxicol 2010, 48:2073–2089.CrossRef 12. Choi S-J, Jae-Min O, Choy J-H: Safety aspect of inorganic layered nanoparticles: size-dependency in vitro and in vivo . J Nanosci Nanotechnol 2008, 8:5297–5301.CrossRef 13. Jinshun Z, Vincent C: Toxicology of nanomaterials used in nanomedicine. J Toxicol Environ Health 2011, 14:593–632.CrossRef 14. Pokharkar V, Dhar S, Bhumkar D, Mali V, Bodhankar S, Prasad BL: Acute and subacute toxicity studies of chitosan reduced gold nanoparticles: a novel carrier for therapeutic agents. J Biomed Nanotechnol 2009, 5:233–239.CrossRef 15. Paul TG: Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician 2005,71(6):1105–1110. 16. Pettersson J, Hindorf U, Persson P, Bengtsson T, Malmqvist U, Werkström V, Ekelund M: Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol 2008,65(2):253–259.CrossRef 17. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N: Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005, 41:380–382.CrossRef 18.
No related posts.